glp-1 trials near me Many people remain excluded from clinical for weight loss The GLP-1 muscle loss headlines

Similarly, with rapid weight and fat pad loss, your skin may not be elastic enough to reduce in size and area as well, leading to sagging skin and soft tissue

For the GLP-1 companion programme specifically, the evidence is more recent and still emerging

According to FDA prescribing information, these effects vary by product and dose: For Ozempic (diabetes treatment): Nausea (15-20% of patients) Diarrhea (8-9% of patients) Vomiting (5-9% of patients) Constipation (3-7% of patients) Abdominal pain (5-6% of patients) For Wegovy (weight management), gastrointestinal effects are more common at the higher therapeutic dose: Nausea (up to 44% of patients) Diarrhea (up to 30% of patients) Vomiting (up to 24% of patients) Constipation (up to 24% of patients) Abdominal pain (up to 20% of patients) These effects are generally mild to moderate and tend to diminish with continued use

Sterne JA, Hernn MA, Reeves BC, et al

10.2337/dc10-1949 15 ChaA